Best Practices
Do You Have Visibility into Your CRO’s processes?
We are cost-conscious, financially responsible, and considerate of budgets, yet understand and clearly communicate how additional activities could add value and reduce time to market.
July 6, 2021
Does Your CRO Value Every Single Patient?
Every patient counts. While large-scale intricately-designed studies can afford to lose patients, clinical trials for rare patient populations are not buffered for atrophy. ARG emphasizes that every patient is vital; in fact, we place the utmost importance on every data point in every study.
May 20, 2021
Is Your CRO Experienced in Clinical Trials With No Clear Pathways?
ARG has “been there and done that” when it comes to operationalizing rare disease clinical trials. Our maturity can be seen in creating deep relationships, which allow us to get things done with no preexisting roadmap.
April 5, 2021
Does Your CRO Understand the Ultimate Trial Goal?
ARG's primary goal is to improve and prolong the lives of the people affected by rare diseases through the clinical trials we manage. We realize our patient-centric approach by carefully cultivating relationships, fostering meaningful communication, and anticipating and addressing all of the challenges in our studies.
May 23, 2019
Does Your CRO Innovate To Keep Trials On Track?
ARG knows from experience that the willingness to be flexible has fueled our success in rare disease clinical trials, resulting in approvals with over $3B in sales.
May 9, 2018
Is Your CRO a Genuine Operational Partner?
ARG's history of successfully operationalizing rare disease clinical research has been driven by comprehensive engagement with our sponsors.
April 6, 2018